Compare Stocks: IDYA, SMMT, BBIO, and HALO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$66.04 +0.4%	$76.79	$51.85 ▼ $93.42	$12.92B	0.97	2.90 million shs	737,018 shs
HALO Halozyme Therapeutics	$108.36 -1.9%	$102.42	$61.22 ▼ $116.85	$12.30B	0.88	1.92 million shs	668,243 shs
IDYA IDEAYA Biosciences	$38.50 +0.2%	$38.02	$26.05 ▼ $42.68	$3.38B	-0.07	1.04 million shs	111,731 shs
SMMT Summit Therapeutics	$17.38 +2.7%	$15.01	$12.07 ▼ $29.23	$13.86B	-1.24	4.54 million shs	3.27 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-0.26%	+0.14%	-14.09%	-14.76%	+26.68%
HALO Halozyme Therapeutics	-1.04%	-1.81%	+3.67%	+38.96%	+50.53%
IDYA IDEAYA Biosciences	+1.72%	+2.80%	-3.97%	+2.28%	+41.53%
SMMT Summit Therapeutics	+3.17%	+2.80%	+24.16%	+9.66%	-18.15%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$66.04 +0.4%	$76.79	$51.85 ▼ $93.42	$12.92B	0.97	2.90 million shs	737,018 shs
HALO Halozyme Therapeutics	$108.36 -1.9%	$102.42	$61.22 ▼ $116.85	$12.30B	0.88	1.92 million shs	668,243 shs
IDYA IDEAYA Biosciences	$38.50 +0.2%	$38.02	$26.05 ▼ $42.68	$3.38B	-0.07	1.04 million shs	111,731 shs
SMMT Summit Therapeutics	$17.38 +2.7%	$15.01	$12.07 ▼ $29.23	$13.86B	-1.24	4.54 million shs	3.27 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-0.26%	+0.14%	-14.09%	-14.76%	+26.68%
HALO Halozyme Therapeutics	-1.04%	-1.81%	+3.67%	+38.96%	+50.53%
IDYA IDEAYA Biosciences	+1.72%	+2.80%	-3.97%	+2.28%	+41.53%
SMMT Summit Therapeutics	+3.17%	+2.80%	+24.16%	+9.66%	-18.15%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.83	Moderate Buy	$102.61	55.37% Upside
HALO Halozyme Therapeutics	2.62	Moderate Buy	$91.20	-15.83% Downside
IDYA IDEAYA Biosciences	2.80	Moderate Buy	$52.69	36.88% Upside
SMMT Summit Therapeutics	2.53	Moderate Buy	$28.61	64.65% Upside

Current Analyst Ratings Breakdown

Latest IDYA, SMMT, BBIO, and HALO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/1/2026	SMMT Summit Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$18.00 ➝ $20.00
9/30/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/29/2026	SMMT Summit Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$41.00
9/29/2026	SMMT Summit Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform
9/29/2026	SMMT Summit Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$30.00
9/25/2026	BBIO BridgeBio Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
9/25/2026	SMMT Summit Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00 ➝ $43.00
9/23/2026	SMMT Summit Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/23/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/22/2026	IDYA IDEAYA Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/22/2026	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight

(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$502.08M	25.71	N/A	N/A	($10.77) per share	-6.13
HALO Halozyme Therapeutics	$1.66B	7.39	$4.63 per share	23.38	$0.42 per share	257.99
IDYA IDEAYA Biosciences	$218.71M	15.46	N/A	N/A	$11.67 per share	3.30
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$724.93M	-$3.57	N/A	N/A	N/A	-97.03%	N/A	-61.19%	10/28/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$3.35	32.34	11.61	0.42	24.86%	260.98%	23.91%	11/2/2026 (Estimated)
IDYA IDEAYA Biosciences	-$113.70M	-$1.94	N/A	N/A	N/A	-75.93%	-16.73%	-15.34%	11/9/2026 (Estimated)
SMMT Summit Therapeutics	-$1.08B	-$1.12	N/A	N/A	N/A	N/A	-168.94%	-141.92%	10/19/2026 (Estimated)

Latest IDYA, SMMT, BBIO, and HALO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/28/2026	Q3 2026	BBIO BridgeBio Pharma	-$0.6131	N/A	N/A	N/A	$268.99 million	N/A
10/19/2026	Q3 2026	SMMT Summit Therapeutics	-$0.28	N/A	N/A	N/A	$0.07 million	N/A
8/10/2026	Q2 2026	BBIO BridgeBio Pharma	-$0.5756	-$0.78	-$0.2044	-$0.78	$220.91 million	$243.68 million
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/4/2026	Q2 2026	IDYA IDEAYA Biosciences	-$1.06	-$1.22	-$0.16	-$1.22	$8.02 million	$8.86 million
7/23/2026	Q2 2026	SMMT Summit Therapeutics	-$0.2744	-$0.28	-$0.0056	-$0.28	$0.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	1.23	1.17
HALO Halozyme Therapeutics	13.50	2.71	2.31
IDYA IDEAYA Biosciences	N/A	10.45	10.45
SMMT Summit Therapeutics	N/A	6.96	6.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
HALO Halozyme Therapeutics	97.79%
IDYA IDEAYA Biosciences	98.29%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	14.23%
HALO Halozyme Therapeutics	2.50%
IDYA IDEAYA Biosciences	4.70%
SMMT Summit Therapeutics	83.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	839	195.49 million	167.67 million	Optionable
HALO Halozyme Therapeutics	423	113.50 million	110.66 million	Optionable
IDYA IDEAYA Biosciences	145	87.86 million	83.73 million	Optionable
SMMT Summit Therapeutics	265	797.75 million	131.63 million	Optionable

IDYA, SMMT, BBIO, and HALO Headlines

Recent News About These Companies

AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets

September 30 at 12:52 PM | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Argenx Se (ARGX) and Obsidian Therapeutics (OBX)

September 30 at 12:52 PM | theglobeandmail.com

Summit Therapeutics (NASDAQ:SMMT) Stock Price Up 7.1% - What's Next?

September 30 at 12:20 PM | marketbeat.com

AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets

September 30 at 11:17 AM | 247wallst.com

AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says

September 30 at 1:03 AM | finance.yahoo.com

Summit Therapeutics PLC ADR (SMMT)

September 30 at 1:03 AM | ca.investing.com

Summit Shares Jump on $2B Strategic Investment From AstraZeneca

September 29 at 1:40 PM | zacks.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - Still a Buy?

September 29 at 10:59 AM | marketbeat.com

Summit Therapeutics jumps 20% after AstraZeneca's $2 billion bet: what it signals

September 29 at 7:38 AM | invezz.comI

AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal

September 29 at 2:52 AM | proactiveinvestors.com

AstraZeneca Invests $2 Billion In Summit, Expands Cancer Drug Collaboration; Stock Up

September 28 at 11:59 PM | rttnews.com

Summit Therapeutics rises after AstraZeneca commits $2B investment

September 28 at 6:58 PM | msn.com

Summit shares surge after-hours on $2 billion AstraZeneca equity deal

September 28 at 6:58 PM | finance.yahoo.com

AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs

September 28 at 6:27 PM | wsj.com

AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up

September 28 at 6:14 PM | reuters.com

AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics

September 28 at 5:30 PM | businesswire.com

Bank of America Corp DE Makes New Investment in Summit Therapeutics PLC $SMMT

September 26, 2026 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Earns Neutral Rating from HC Wainwright

September 25, 2026 | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Receives "Neutral" Rating from HC Wainwright

September 23, 2026 | marketbeat.com

HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract ...

September 22, 2026 | marketscreener.comM

Barclays Keeps Their Hold Rating on Summit Therapeutics (SMMT)

September 22, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA, SMMT, BBIO, and HALO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$66.04 +0.24 (+0.37%)

As of 12:43 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Halozyme Therapeutics NASDAQ:HALO

$108.36 -2.05 (-1.85%)

As of 12:43 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

IDEAYA Biosciences NASDAQ:IDYA

$38.49 +0.08 (+0.20%)

As of 12:43 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Summit Therapeutics NASDAQ:SMMT

$17.38 +0.47 (+2.75%)

As of 12:43 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IDYA, SMMT, BBIO, and HALO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IDYA, SMMT, BBIO, and HALO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IDYA, SMMT, BBIO, and HALO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA, SMMT, BBIO, and HALO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

Halozyme Therapeutics NASDAQ:HALO

IDEAYA Biosciences NASDAQ:IDYA

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IDYA, SMMT, BBIO, and HALO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IDYA, SMMT, BBIO, and HALO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IDYA, SMMT, BBIO, and HALO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA, SMMT, BBIO, and HALO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

Halozyme Therapeutics NASDAQ:HALO

IDEAYA Biosciences NASDAQ:IDYA

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools